Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. 1998

R K Pandita, and K Persson, and P Hedlund, and K E Andersson
Department of Clinical Pharmacology, Lund University Hospital, Sweden.

BACKGROUND Testosterone treatment of rats produces prostatic hypertrophy and detrusor overactivity. Whether or not the detrusor overactivity can be related to an increase in the responsiveness of lower urinary tract smooth muscles is not known. METHODS Male Sprague-Dawley rats were given daily injections of testosterone propionate for 2 weeks. Effects on cystometric parameters and on the responsiveness of isolated detrusor, urethral, and prostate smooth muscle preparations to drugs and electrical field stimulation were investigated. RESULTS Testosterone treatment increased prostatic weight twofold (controls, 768 mg; testosterone-treated, 1,478 mg), but not bladder weight (103 mg vs. 116 mg). Micturition pressure (77%), bladder capacity (75%), residual volume (56%), and micturition volume (83%) increased significantly in treated animals, and bladder overactivity developed. No effect of intraarterial doxazosin on these changes was observed. The differences in urodynamic parameters between control and testosterone-treated rats could not be correlated with changes in bladder, urethral, or prostate excitatory innervation, as revealed by responses to electrical field stimulation, or by smooth muscle responses to different contractant drugs. CONCLUSIONS Some of the urodynamic effects seen after testosterone treatment seem to be caused by the mechanical obstruction of the enlarged prostate. Since there were no changes in smooth muscle responsiveness, it is suggested that the bladder overactivity observed can partly be related to testosterone-induced changes of the micturition reflex at the lower urinary tract, spinal, and/or supraspinal levels.

UI MeSH Term Description Entries
D006984 Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA). Hypertrophies
D008297 Male Males
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D014554 Urination Discharge of URINE, liquid waste processed by the KIDNEY, from the body. Micturition
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017292 Doxazosin A prazosin-related compound that is a selective alpha-1-adrenergic blocker. Doxazosin Mesylate,1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine,Alfamedin,Apo-Doxazosin,Cardular,Cardura,Carduran,Carduran Neo,Diblocin,Doxa-Puren,DoxaUro,Doxacor,Doxagamma,Doxamax,Doxatensa,Doxazomerck,Doxazosin AL,Doxazosin AZU,Doxazosin Apogepha,Doxazosin Heumann,Doxazosin Klast,Doxazosin Monohydrochloride,Doxazosin Stada,Doxazosin Von Ct,Doxazosin beta,Doxazosin findusFit,Doxazosin-Wolff,Doxazosin-ratiopharm,Doxazosina Alter,Doxazosina Cinfa,Doxazosina Combino Pharm,Doxazosina Geminis,Doxazosina Normon,Doxazosina Pharmagenus,Doxazosina Ratiopharm,Doxazosina Ur,Gen-Doxazosin,Jutalar,MTW-Doxazosin,Novo-Doxazosin,Progandol Neo,UK-33274,Uriduct,Zoxan,ratio-Doxazosin,Apo Doxazosin,Ct, Doxazosin Von,Doxa Puren,Doxazosin Wolff,Doxazosin ratiopharm,Gen Doxazosin,MTW Doxazosin,Mesylate, Doxazosin,Monohydrochloride, Doxazosin,Neo, Carduran,Novo Doxazosin,Ratiopharm, Doxazosina,UK 33274,UK33274,Von Ct, Doxazosin,ratio Doxazosin
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

R K Pandita, and K Persson, and P Hedlund, and K E Andersson
January 2015, Urologiia (Moscow, Russia : 1999),
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
January 1998, European journal of pharmacology,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
February 2021, Scandinavian journal of urology,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
October 2021, Physiological measurement,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
July 2006, Autonomic & autacoid pharmacology,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
August 1998, Japanese journal of pharmacology,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
December 1976, British journal of urology,
R K Pandita, and K Persson, and P Hedlund, and K E Andersson
January 2002, Scandinavian journal of urology and nephrology. Supplementum,
Copied contents to your clipboard!